Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-14T07:17:06.556Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-Term Use of Rivastigmine in Patients With Dementia With Lewy Bodies: An Open-Label Trial

Published online by Cambridge University Press:  10 January 2005

Janet Grace ,
Sarah Daniel ,
Timothy Stevens ,
K. K. Shankar ,
Zuzanna Walker ,
E. Jane Byrne ,
Susan Butler ,
David Wilkinson ,
Jan Woolford  and
Jonathon Waite
...Show all authors
Janet Grace
Affiliation:
Newcastle General Hospital, Newcastle upon Tyne, UK
Sarah Daniel
Affiliation:
Newcastle General Hospital, Newcastle upon Tyne, UK
Timothy Stevens
Affiliation:
Royal Free and University College London Medical School, London, UK
K. K. Shankar
Affiliation:
St. Margaret's Hospital, Essex, UK
Zuzanna Walker
Affiliation:
Royal Free and University College London Medical School, London, UK
E. Jane Byrne
Affiliation:
Department of Old Age Psychiatry, Withington Hospital, Manchester, UK
Susan Butler
Affiliation:
Department of Old Age Psychiatry, Withington Hospital, Manchester, UK
David Wilkinson
Affiliation:
Thornhill Research Unit, Southampton, UK
Jan Woolford
Affiliation:
Thornhill Research Unit, Southampton, UK
Jonathon Waite
Affiliation:
University Hospital, Nottingham, UK.
Ian G. McKeith
Affiliation:
Newcastle General Hospital, Newcastle upon Tyne, UK
Get access Rights & Permissions [Opens in a new window]

Abstract

Patients with dementia with lewy bodies (DLB) have progressive deficits in cognition, parkinsonism, and neuropsychiatric symptoms. Cholinesterase inhibitors have been used to ameliorate cognitive decline and neuropsychiatric symptoms in short-term trials. In this study, patients with DLB were treated with rivastigmine up to 96 weeks. Improvement from baseline was seen in cognitive function as measured by the Mini-Mental State Examination (MMSE), and neuropsychiatric symptoms as measured by the Neuropsychiatric Inventory (NPI) over the first 24 weeks of treatment. By 96 weeks, neither the MMSE scores nor the NPI scores were significantly worse than at baseline.

Type
Articles
Information
International Psychogeriatrics , Volume 13 , Issue 2 , June 2001 , pp. 199 - 205
Copyright
© 2001 International Psychogeriatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)